Working… Menu

Clinical Trial to Evaluate the Safety and Analgesic Efficacy of VVZ-149 in Lumbar Radiculopathy (Sciatica) (LMR)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02644421
Recruitment Status : Completed
First Posted : December 31, 2015
Last Update Posted : March 19, 2018
Information provided by (Responsible Party):
Christine N. Sang, MD, MPH, Brigham and Women's Hospital

Brief Summary:
Double-blind, crossover, randomized, 3x3 Latin square, placebo-controlled study of single intravenous dose administration of VVZ-149. To demonstrate assay sensitivity, lidocaine will be administered as a positive control. The study will take place during a single inpatient visit involving three separate treatment periods, each with a washout of (>16-hours. Study drugs (VVZ-149 vs. lidocaine vs. normal saline, NS) will be administered intravenously.

Condition or disease Intervention/treatment Phase
Radiculopathy Sciatica Drug: VVZ-149 Drug: Lidocaine Drug: Placebo Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 18 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Phase Ib Randomized, Double-Blind, Latin Square Crossover, Clinical Trial to Evaluate the Safety and Analgesic Efficacy of VVZ-149 v. Lidocaine v. Placebo in Lumbar Radiculopathy
Study Start Date : November 2015
Actual Primary Completion Date : July 2017
Actual Study Completion Date : July 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Sciatica

Arm Intervention/treatment
Experimental: VVZ-149

The following doses will be administered intravenously:

  • Loading Dose: 1.8 mg/kg VVZ-149 over 0.5 hours
  • Maintenance infusion: 1.3 mg/kg/hr VVZ-149 over 7.5 hours
Drug: VVZ-149
Active Comparator: Lidocaine

The following doses will be administered intravenously:

  • Lidocaine 4mg/kg LBM over 0.5 hours
  • Normal saline over 7.5 hours
Drug: Lidocaine
Placebo Comparator: Placebo
Normal saline administered intravenously over 8 hours
Drug: Placebo

Primary Outcome Measures :
  1. Number of subjects with treatment-related Adverse Events as assessed using an internal, categorical severity/relationship scale [ Time Frame: over 8 hour infusion ]
    The number of subjects who report mild, moderate or severe treatment-emergent adverse events that are deemed by the investigator to be possibly, probably, or definitely related to the study medication

Secondary Outcome Measures :
  1. Reduction in Pain Intensity using the 11-pt Likert Pain Intensity Scale [ Time Frame: over 8 hour infusion ]
    Reductions in pain intensity from baseline will be calculated using data obtained over the 8 hour infusion from the 11-pt Likert Pain Intensity Scale

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Subjects must have a history of persistent pain secondary to unilateral monoradiculopathy present for a minimum of 3 months prior to the study, with an average pain intensity score of at least moderate over at least 50% of the day for the 7 days prior to the screening visit and over the 7 days prior to starting study medication.
  2. Males or females between 18 and 70 years of age, inclusive. Females who are pregnant or breastfeeding will be excluded from the trial.
  3. Subjects must be in generally good health, either using no medication or using a stabilized medication regimen for chronic and well-controlled conditions such as hypertension, allergies, stable endocrinopathies (e.g. hypothyroidism), etc. Subjects with other active diseases will be reviewed on a case-by-case basis by the principal investigator.
  4. No concomitant therapy with any medication that is a known significant inhibitor or inducer of CYP450 2D6 and CYP3A4, at the discretion of the PI.
  5. Normal or clinically insignificant screening laboratory tests:

    • Serum BUN, creatinine, bicarbonate, calcium, chloride, potassium, sodium, lactate dehydrogenase, inorganic phosphate, total protein, glucose, albumin, and uric acid. WBC, absolute neutrophil count, hemoglobin, hematocrit, and platelets. SGOT (AST), SGPT (ALT), total bilirubin, alkaline phosphatase, TSH/T4, urinalysis, and urine toxicology screen.
    • Electrocardiogram (12-lead). Any significant laboratory abnormalities will be reviewed by the principal investigator prior to inclusion of the subject in the study.
  6. Willingness to restrict analgesic therapy during inpatient admission days to the allowed rescue analgesic agent permitted by the study (acetaminophen).
  7. Subjects must have normal cognitive function and communicative ability in the English language.
  8. Subjects must be able to provide meaningful written informed consent.
  9. Subjects must be able to maintain complete required questionnaires, and must be able to fulfill all other conditions of the protocol.

Exclusion Criteria:

  1. Female subjects who are pregnant or breastfeeding, or plan to become pregnant while participating in the study.
  2. Subjects with a previous history of multiple or severe drug allergies, including lidocaine.
  3. Subjects with a history of or current chronic substance abuse, including alcohol.
  4. Subjects who have participated in a study of an investigational drug or device within 30 days prior to screening for this study. Subjects must agree not to participate in other investigational drug or device studies during the entire course of this study (beginning with the screening visit).
  5. Subjects with the following abnormal clinical evaluations:

    • Impaired renal function defined as BUN > 45 or creatinine >2.0 and/or impaired liver function defined as liver transaminases, alkaline phosphatase, or bilirubin greater than 1.5 x upper limit of normal laboratory values.
    • Prolonged PR (>200 ms) interval on electrocardiogram (12-lead). Subjects presenting with the above laboratory abnormalities may be allowed on a case-by-case basis at the discretion of the principal investigator.
  6. Subjects who intend to donate blood or blood products while participating in this study, and for 30 days following completion of the study.
  7. Subjects with clinically significant renal, hepatic, or cardiac disease, with seizure disorders, or with a clinical history of life-threatening arrhythmias (i.e. torsades de pointes).
  8. Subjects with a severe neuropsychiatric disorder requiring treatment.
  9. Subjects with sensitivity to amide-type local anesthetics.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02644421

Layout table for location information
United States, Massachusetts
Translational Pain Research, Brigham and Women's Hospital
Boston, Massachusetts, United States, 02115
Sponsors and Collaborators
Brigham and Women's Hospital
Layout table for investigator information
Principal Investigator: Christine N Sang, MD MPH Brigham and Women's Hospital

Layout table for additonal information
Responsible Party: Christine N. Sang, MD, MPH, Director, Translational Pain Research, Brigham and Women's Hospital Identifier: NCT02644421     History of Changes
Other Study ID Numbers: 2015-P-002050
First Posted: December 31, 2015    Key Record Dates
Last Update Posted: March 19, 2018
Last Verified: March 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Keywords provided by Christine N. Sang, MD, MPH, Brigham and Women's Hospital:
Neuropathic Pain
Additional relevant MeSH terms:
Layout table for MeSH terms
Neuromuscular Diseases
Peripheral Nervous System Diseases
Nervous System Diseases
Sciatic Neuropathy
Neurologic Manifestations
Signs and Symptoms
Anesthetics, Local
Central Nervous System Depressants
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents
Anti-Arrhythmia Agents
Voltage-Gated Sodium Channel Blockers
Sodium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action